Journals / Abant Tıp Dergisi / 2013 / Cilt: 2 - Sayı: 1

New adipokines: Leptin, adiponectin and omentin

Yeni adipokinler: Leptin, adiponektin ve omentin

Pages
56–62
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, drugs targeting adipokines that derived from adipose tissue may increase insulin sensitivity and may also have protective effect against atherosclerosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Adipose tissue is now considered as an important part of energy metabolism.
📊
Key Findings & Data:The gene encoding adiponectin is located in a loci in chromosome 3 which is close to the locus considered responsible for type 2 diabetes and steatosis.
💡
Conclusion & Impact:Therefore, drugs targeting adipokines that derived from adipose tissue may increase insulin sensitivity and may also have protective effect against atherosclerosis.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Adipokin · leptin · adiponektin

Abstract

Adipose tissue is now considered as an important part of energy metabolism. Adipokines secreted by adipose tissue play decisive role in many physiological process such as energy balance, insulin and glucose metabolism, lipid metabolism, regulation blood pressure, vascular remodeling, coagulation and inflammation. The amount of body fat organized by leptin, environmental factors and genes together. Leptin molecule was found to be associated with appetite, body weight, energy balance and a number of neuroendocrine functions so far. The gene encoding adiponectin is located in a loci in chromosome 3 which is close to the locus considered responsible for type 2 diabetes and steatosis. Gene expression of omentin-1 and plasma levels of omentin decreased in obese subjects. Obesity related markers such as, waist circumference, body mass index and leptin levels are negatively correlated with plasma omentin levels. Adiponectin has anti-atherogenic and insulin sensitizing effects. Therefore, drugs targeting adipokines that derived from adipose tissue may increase insulin sensitivity and may also have protective effect against atherosclerosis.

Özet

Yağ dokusu günümüzde enerji metabolizmasının önemli bir parçası olarak kabul edilmektedir. Salgıladığı adipokinler beslenme, iştah, enerji dengesi, insülin ve glukoz metabolizması, lipid metabolizması, kan basıncının düzenlenmesi, vasküler remodeling, koagülasyon, inflamasyon gibi vücudun birçok fizyolojik işleminde rol oynamaktadırlar. Leptin, çevresel etmenler ve genler beraberce vücut yağ miktarını düzenlemektedirler. Leptin molekülünün şu ana kadar iştah, vücut ağırlığı, enerji dengesi ve bir takım nöroendokrin fonksiyonlarla ilişkili olduğu saptanmıştır. Yağ dokusundan salgılanan adiponektini kodlayan gen 3. kromozom üzerinde olup bulunduğu loküs tip 2 diyabet ve vücut yağlanmasından sorumlu tutulan loküse yakındır. Obez bireylerde omentin 1’in hem yağ dokusundaki gen ekspresyonu ve hem de plazma seviyeleri azalmaktadır. Bel çevresi, vücut kitle indeksi ve leptin seviyleri gibi obezite ile ilişkili markerlar ile omentin seviyesi ters orantılıdır. Adiponektinin anti-aterojenik ve insülin duyarlığını artırıcı etkileri mevcuttur. Bu nedenle yağ dokusu kökenli bu adipokinleri hedef alan ilaç tedavileri insülin duyarlılığını artırabilir ayrıca ateroskleroza karşı koruyucu etki gösterebilir.

🔖

Cite This Article

AKTAŞ, G., TEKÇE, H., ŞİT, M. (2022). New adipokines: Leptin, adiponectin and omentin. Abant Tıp Dergisi, Cilt: 2 - Sayı: 1, 56–62. https://ajindex.com/articles/427231

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lau DCW, Dhillon B, Yan HY, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol-Heart C. 2005;288(5):H2031-H41
  2. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Current atherosclerosis reports. 2004;6(6):424-31. Epub 2004/10/16
  3. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. The New England journal of medicine. 1996;334(5):292-5. Epub 1996/02/01
  4. Friedman JM, Leibel RL. Tackling a weighty problem. Cell. 1992;69(2):217-20. Epub 1992/04/17
  5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-32. Epub 1994/12/01
  6. Maffei M, Stoffel M, Barone M, Moon B, Dammerman M, Ravussin E, Bogardus C, Ludwig DS, Flier JS, Talley M, et al. Absence of mutations in the human OB gene in obese/diabetic subjects. Diabetes. 1996;45(5):679-82. Epub 1996/05/01
  7. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, ORahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903-8
  8. Lau D, Yan H, Abdel-Hafez M, Kermouni A. Adipokines and the paracrine control of their production in obesity and diabetes. Int J Obes Relat Metab Disord. 2002;26(Suppl 1):S111
  9. Mantzoros C, Flier JS, Lesem MD, Brewerton TD, Jimerson DC. Cerebrospinal fluid leptin in anorexia nervosa: Correlation with nutritional status and potential role in resistance to weight gain. J Clin Endocr Metab. 1997;82(6):1845-51
  10. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004;59:305-31
  11. Mounzih K, Lu RH, Chehab FF. Leptin treatment rescues the sterility of genetically obese ob/ob males. Endocrinology. 1997;138(3):1190-3
  12. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes. 2004;53:S152-S8
  13. Cohen P, Zhao C, Cai XL, Montez JM, Rohani SC, Feinstein P, Mombaerts P, Friedman JM. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest. 2001;108(8):1113-21
  14. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, B